Business ❯ Pharmaceuticals

Vaccine Development

Moderna Novavax Market Impact Collaboration Agreements Research and Development AstraZeneca mRNA Technology Market Reactions Corporate Governance Contracts Corporate Communication Market Response Pricing Strategies Market Competition Manufacturing Funding COVID-19 Vaccines Manufacturers Regulatory Affairs Valneva SE Valneva COVID-19 Vaccine Research Funding Investment Decisions Covid-19 Vaccines Seattle-based Cancer Vaccine Pfizer Moderna Inc. Clinical Trials Corporate Deals

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

The move follows fresh post‑marketing data that regulators say show the live vaccine can cause chikungunya‑like illness in some recipients.

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine